MCID: PRM108
MIFTS: 50

Primary Progressive Multiple Sclerosis

Categories: Genetic diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Primary Progressive Multiple Sclerosis

MalaCards integrated aliases for Primary Progressive Multiple Sclerosis:

Name: Primary Progressive Multiple Sclerosis 12 51 14
Multiple Sclerosis, Primary Progressive 69
Primary-Progressive Ms 12
Ppms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050784
MeSH 41 D020528
SNOMED-CT 64 428700003
UMLS 69 C0751964

Summaries for Primary Progressive Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterized by steady worsening of neurologic functioning, without any distinct relapses or periods of remission. The rate of progression may vary over time, with occasional plateaus or temporary improvements, but the progression is continuous.

MalaCards based summary : Primary Progressive Multiple Sclerosis, also known as multiple sclerosis, primary progressive, is related to asthma and multiple sclerosis. An important gene associated with Primary Progressive Multiple Sclerosis is IFNB1 (Interferon Beta 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs 4-Aminopyridine and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include b cells, brain and t cells, and related phenotypes are hematopoietic system and cellular

Related Diseases for Primary Progressive Multiple Sclerosis

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Primary Progressive Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 127)
# Related Disease Score Top Affiliating Genes
1 asthma 29.3 ICAM1 IL10 MMP9 TNF VCAM1
2 multiple sclerosis 28.4 ICAM1 IFNB1 IL10 IL7R MBP MMP9
3 mental retardation, x-linked, syndromic 13 11.9
4 fetal methylmercury syndrome 11.2
5 punctate inner choroidopathy 10.5 IL10 TNF
6 tropical endomyocardial fibrosis 10.5 IL10 TNF
7 microscopic polyangiitis 10.5 IL10 TNF
8 multifocal choroiditis 10.5 IL10 TNF
9 tungiasis 10.5 IL10 TNF
10 endomyocardial fibrosis 10.5 IL10 TNF
11 acute transverse myelitis 10.5 IL10 MMP9
12 transient hypogammaglobulinemia 10.5 IL10 TNF
13 marburg hemorrhagic fever 10.5 IFNB1 TNF
14 scleritis 10.4 MMP9 TNF
15 choroiditis 10.4 IL10 TNF
16 mucocutaneous leishmaniasis 10.4 IL10 TNF
17 idiopathic achalasia 10.4 IL10 TNF
18 trichuriasis 10.4 IL10 TNF
19 clonorchiasis 10.4 IL10 TNF
20 appendicitis 10.4 IL10 MMP9 TNF
21 bronchiolitis obliterans 10.3 IL10 MMP9 TNF
22 poliomyelitis 10.3 ICAM1 IL10 TNF
23 allergic hypersensitivity disease 10.3
24 plasmodium vivax malaria 10.3 ICAM1 IL10 TNF
25 lepromatous leprosy 10.3 ICAM1 IL10 TNF
26 nose disease 10.3 ICAM1 IL10 TNF
27 meningitis 10.3 IL10 MMP9 TNF
28 periodontitis 10.3 IL10 MMP9 TNF
29 parasitic protozoa infectious disease 10.3 ICAM1 IL10 TNF
30 kawasaki disease 10.3 IL10 MMP9 TNF
31 pulmonary edema 10.3 ICAM1 IL10 TNF
32 pediatric multiple sclerosis 10.3 MMP9 MOG
33 extrinsic cardiomyopathy 10.3 IFNB1 IL10 TNF
34 allergic contact dermatitis 10.3 ICAM1 IL10 TNF
35 lymphadenitis 10.3 ICAM1 IL10 TNF
36 alcoholic hepatitis 10.3 ICAM1 IL10 TNF
37 autoimmune myocarditis 10.3 TNF VCAM1
38 interstitial lung disease 10.3 IL10 MMP9 TNF
39 contact dermatitis 10.3 ICAM1 IL10 TNF
40 peritonitis 10.3 ICAM1 IL10 TNF
41 plasmodium falciparum malaria 10.3 ICAM1 IL10 TNF
42 rubella 10.3 IL10 MOG TNF
43 uveitis 10.3 ICAM1 IL10 TNF
44 lymphocytic vasculitis 10.3 ICAM1 VCAM1
45 cortical thymoma 10.2 ICAM1 VCAM1
46 listeria meningitis 10.2 IFNB1 TNF
47 mooren's ulcer 10.2 ICAM1 VCAM1
48 orofacial granulomatosis 10.2 IL10 TNF
49 root caries 10.2
50 niemann-pick disease, type a 10.2 MBP PLP1

Graphical network of the top 20 diseases related to Primary Progressive Multiple Sclerosis:



Diseases related to Primary Progressive Multiple Sclerosis

Symptoms & Phenotypes for Primary Progressive Multiple Sclerosis

MGI Mouse Phenotypes related to Primary Progressive Multiple Sclerosis:

43 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 TNF MOG VCAM1 PLP1 IFNB1 MMP9
2 cellular MP:0005384 10.21 PLP1 TNF MOG VCAM1 MBP MMP9
3 homeostasis/metabolism MP:0005376 10.2 PLP1 S100B TNF VCAM1 OMG MBP
4 immune system MP:0005387 10.17 PLP1 TNF MOG VCAM1 IFNB1 MMP9
5 growth/size/body region MP:0005378 10.15 PLP1 MMP9 TNF MOG VCAM1 ICAM1
6 nervous system MP:0003631 9.97 PLP1 MMP9 TNF MOG ICAM1 MBP
7 muscle MP:0005369 9.88 PLP1 MMP9 TNF MOG ICAM1 IL10
8 neoplasm MP:0002006 9.85 TNF IFNB1 MMP9 IL10 IL7R ICAM1
9 no phenotypic analysis MP:0003012 9.73 TNF VCAM1 OMG IFNB1 IL10 CSF1R
10 normal MP:0002873 9.7 S100B OMG MBP IFNB1 IL10 CSF1R
11 reproductive system MP:0005389 9.5 PLP1 MMP9 TNF VCAM1 MBP IL10
12 vision/eye MP:0005391 9.17 PLP1 MMP9 TNF MOG MBP IL10

Drugs & Therapeutics for Primary Progressive Multiple Sclerosis

Drugs for Primary Progressive Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
4-Aminopyridine Approved Phase 4 504-24-5 1727
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
4 Hormone Antagonists Phase 4,Phase 2,Phase 1
5 Hormones Phase 4,Phase 2,Phase 1
6 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
7 Potassium Channel Blockers Phase 4
8 Antineoplastic Agents, Hormonal Phase 4
9 glucocorticoids Phase 4
10
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696
11
Morphine Approved, Investigational Phase 3 57-27-2 5288826
12
Hydroxyurea Approved Phase 2, Phase 3 127-07-1 3657
13 Antirheumatic Agents Phase 2, Phase 3,Phase 1
14 Immunosuppressive Agents Phase 3,Phase 2
15 Fingolimod Hydrochloride Phase 3
16 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
17
Natalizumab Approved, Investigational Phase 2 189261-10-7
18
Ibudilast Approved, Investigational Phase 2 50847-11-5 3671
19
Dimethyl fumarate Approved, Investigational Phase 2 624-49-7 5271565 637568
20
Hydroxychloroquine Approved Phase 2 118-42-3 3652
21
Glatiramer Acetate Approved, Investigational Phase 2 147245-92-9 3081884
22
Norethindrone Approved Phase 2 68-22-4 6230
23
Idebenone Approved, Investigational Phase 1, Phase 2 58186-27-9
24
Dronabinol Approved, Illicit Phase 1, Phase 2 1972-08-3 16078 2978
25 Andrographolide Investigational Phase 1, Phase 2 5508-58-7
26 Analgesics Phase 1, Phase 2
27 Analgesics, Non-Narcotic Phase 1, Phase 2
28 Anti-Infective Agents Phase 1, Phase 2
29 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
30 Antiparasitic Agents Phase 1, Phase 2
31 Antiprotozoal Agents Phase 1, Phase 2
32 Antiviral Agents Phase 1, Phase 2
33 Peripheral Nervous System Agents Phase 1, Phase 2
34 Platelet Aggregation Inhibitors Phase 1, Phase 2
35 Anti-Asthmatic Agents Phase 2
36 Autonomic Agents Phase 2
37 Bronchodilator Agents Phase 2
38 Phosphodiesterase Inhibitors Phase 2
39 Respiratory System Agents Phase 2,Phase 1
40 Vasodilator Agents Phase 2,Phase 1
41 Dermatologic Agents Phase 2,Phase 1
42 Antioxidants Phase 1, Phase 2
43 Micronutrients Phase 1, Phase 2
44 Protective Agents Phase 1, Phase 2
45 Trace Elements Phase 1, Phase 2
46 Ubiquinone Phase 1, Phase 2
47 Antimalarials Phase 2
48 Adjuvants, Immunologic Phase 2
49 Contraceptive Agents Phase 2
50 Contraceptives, Oral Phase 2

Interventional clinical trials:

(show all 39)

# Name Status NCT ID Phase Drugs
1 A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Active, not recruiting NCT02208050 Phase 4 Fampridine;Placebo
2 Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis Terminated NCT01411514 Phase 4 Prednisone;Placebo
3 A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis Completed NCT00087529 Phase 2, Phase 3 placebo;rituximab
4 Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity Completed NCT01538225 Phase 3 Sativex®;Placebo
5 Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) Recruiting NCT02688985 Phase 3 Ocrelizumab
6 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis Recruiting NCT01433497 Phase 2, Phase 3 masitinib;placebo
7 A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis Active, not recruiting NCT01194570 Phase 3 Ocrelizumab
8 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Active, not recruiting NCT02220244 Phase 3 MD1003 100mg capsule
9 This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. Terminated NCT00731692 Phase 3 FTY720;Placebo
10 Hydroxyurea in Primary Progressive Multiple Sclerosis Terminated NCT01103583 Phase 2, Phase 3 Hydroxyurea
11 Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Unknown status NCT02273635 Phase 1, Phase 2 Andrographolides;placebo
12 A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo Completed NCT02284568 Phase 2 Laquinimod;Placebo
13 Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS) Completed NCT01450488 Phase 2 masitinib;masitinib
14 Natalizumab Treatment of Progressive Multiple Sclerosis Completed NCT01077466 Phase 2 Natalizumab
15 Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis Completed NCT01191996 Phase 1, Phase 2
16 Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Completed NCT01982942 Phase 2 ibudilast;Placebo
17 Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis Recruiting NCT02959658 Phase 2 Dimethyl Fumarate;Placebo Oral Capsule
18 Hydroxychloroquine in Primary Progressive Multiple Sclerosis Recruiting NCT02913157 Phase 2 Hydroxychloroquine
19 Safety and Efficacy of Monthly Long-acting IM Injection of 40 mg GA Depot in Subjects With PPMS Recruiting NCT03362294 Phase 2 GA Depot 40mg once monthly
20 Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition Recruiting NCT01466114 Phase 2 estriol;Norethindrone
21 ACTH in Progressive Forms of MS Recruiting NCT01950234 Phase 2 ACTH;Placebo
22 Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS) Active, not recruiting NCT00950248 Phase 1, Phase 2 Idebenone
23 Idebenone for Primary Progressive Multiple Sclerosis Enrolling by invitation NCT01854359 Phase 1, Phase 2 Idebenone
24 Cannabis for Spasticity in Multiple Sclerosis Terminated NCT00682929 Phase 1, Phase 2 Inhaled Cannabis;Oral THC;Placebo
25 Cannabis for Spasticity in Multiple Sclerosis Terminated NCT00260741 Phase 1, Phase 2 Smoked Cannabis
26 Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) Completed NCT01381354 Phase 1
27 A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients Completed NCT02253264 Phase 1 Rituximab
28 Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis Recruiting NCT03283826 Phase 1 ATA188
29 Tear Analysis in the Diagnosis of Multiple Sclerosis Completed NCT02016222
30 Supported Treadmill Training for Progressive Multiple Sclerosis Completed NCT01339234
31 Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina Completed NCT01080014
32 Wahls Paleo Diet and Progressive Multiple Sclerosis Completed NCT01915433
33 Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis Recruiting NCT03094364
34 MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis Recruiting NCT02845635
35 Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients Recruiting NCT02789670
36 Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study Active, not recruiting NCT01776060
37 Mitochondrial Dysfunction and Disease Progression Active, not recruiting NCT02549703
38 Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis No longer available NCT02807285 Ocrelizumab
39 Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis Terminated NCT01723631

Search NIH Clinical Center for Primary Progressive Multiple Sclerosis

Genetic Tests for Primary Progressive Multiple Sclerosis

Anatomical Context for Primary Progressive Multiple Sclerosis

MalaCards organs/tissues related to Primary Progressive Multiple Sclerosis:

38
B Cells, Brain, T Cells, Spinal Cord, Lymph Node

Publications for Primary Progressive Multiple Sclerosis

Articles related to Primary Progressive Multiple Sclerosis:

(show top 50) (show all 87)
# Title Authors Year
1
Looking into cognitive impairment in primary-progressive multiple sclerosis. ( 29053884 )
2018
2
Global transcriptome profiling of mild relapsing-remitting versus primary progressive multiple sclerosis. ( 29316044 )
2018
3
Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis. ( 29284602 )
2018
4
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. ( 28002688 )
2017
5
CSF profile in primary progressive multiple sclerosis: Re-exploring the basics. ( 28797088 )
2017
6
A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry. ( 28524746 )
2017
7
Smoking does not influence disability accumulation in primary progressive multiple sclerosis. ( 28239937 )
2017
8
A composite measure to explore visual disability in primary progressive multiple sclerosis. ( 28607759 )
2017
9
Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis. ( 28939685 )
2017
10
Altered neural mechanisms of cognitive control in patients with primary progressive multiple sclerosis: An effective connectivity study. ( 28205364 )
2017
11
CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis. ( 28870573 )
2017
12
Synchronization and variability imbalance underlie cognitive impairment in primary-progressive multiple sclerosis. ( 28429774 )
2017
13
The MRZ reaction in primary progressive multiple sclerosis. ( 28166789 )
2017
14
FDA approves first drug for primary progressive multiple sclerosis. ( 28450720 )
2017
15
Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. ( 29053836 )
2017
16
Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case. ( 28401768 )
2017
17
Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis. ( 29232960 )
2017
18
Aberrant expression of I^-catenin in CD4(+) T cells isolated from primary progressive multiple sclerosis patients. ( 28578105 )
2017
19
Primary Progressive Multiple Sclerosis: Putting Together the Puzzle. ( 28620346 )
2017
20
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. ( 26827074 )
2016
21
Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis. ( 27778334 )
2016
22
Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions? ( 26993116 )
2016
23
CSF1R-related leukoencephalopathy mimicking primary progressive multiple sclerosis. ( 27314966 )
2016
24
Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal. ( 27159986 )
2016
25
Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives. ( 27813441 )
2016
26
Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study. ( 26785711 )
2016
27
Primary progressive multiple sclerosis--why we are failing. ( 26827076 )
2016
28
A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study. ( 27072687 )
2016
29
Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index. ( 26706657 )
2016
30
Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. ( 26599831 )
2016
31
Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. ( 25903918 )
2015
32
Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review. ( 26393519 )
2015
33
Association of Deep Gray Matter Damage With Cortical and Spinal Cord Degeneration in Primary Progressive Multiple Sclerosis. ( 26457955 )
2015
34
Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis. ( 25863355 )
2015
35
Melatonin treatment improves primary progressive multiple sclerosis: a case report. ( 25546814 )
2015
36
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. ( 25468777 )
2015
37
Paroxetine-Related Adult-Onset Tic Disorder: A Presentation of Primary Progressive Multiple Sclerosis. ( 26222974 )
2015
38
PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. ( 25994655 )
2015
39
Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis. ( 26485710 )
2015
40
Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review. ( 25802867 )
2015
41
Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study. ( 26246109 )
2015
42
Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. ( 25583839 )
2015
43
Multimodal neurophysiological evaluation of primary progressive multiple sclerosis - An increasingly valid biomarker, with limits. ( 26590670 )
2015
44
Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis? ( 26263977 )
2015
45
Modelling the natural history of primary progressive multiple sclerosis. ( 24828900 )
2014
46
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review. ( 24651401 )
2014
47
Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. ( 25311247 )
2014
48
Epstein-barr virus in the central nervous system and cervical lymph node of a patient with primary progressive multiple sclerosis. ( 24918642 )
2014
49
Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. ( 24909126 )
2014
50
Adult-onset vanishing white matter disease as differential diagnosis of primary progressive multiple sclerosis: A case report. ( 25135182 )
2014

Variations for Primary Progressive Multiple Sclerosis

Expression for Primary Progressive Multiple Sclerosis

Search GEO for disease gene expression data for Primary Progressive Multiple Sclerosis.

Pathways for Primary Progressive Multiple Sclerosis

Pathways related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 CSF1R ICAM1 IFNB1 IL10 IL7R MMP9
2
Show member pathways
13.15 CSF1R ICAM1 IFNB1 IL10 IL7R MMP9
3
Show member pathways
12.42 ICAM1 IFNB1 MMP9 TNF
4 12.03 IL10 PLP1 TNF
5
Show member pathways
12.01 IFNB1 IL10 TNF
6 11.95 ICAM1 MMP9 TNF VCAM1
7 11.91 CSF1R IFNB1 TNF
8 11.88 ICAM1 MMP9 VCAM1
9 11.85 IL10 IL7R TNF
10 11.81 ICAM1 MMP9 TNF VCAM1
11 11.76 ICAM1 TNF VCAM1
12 11.75 CSF1R IL7R TNF
13 11.73 ICAM1 TNF VCAM1
14 11.73 CSF1R IFNB1 IL10 IL7R
15 11.73 ICAM1 MBP MMP9 OMG TNF
16 11.65 IL10 IL7R TNF
17 11.52 ICAM1 IL10 TNF VCAM1
18
Show member pathways
11.47 ICAM1 MMP9 TNF VCAM1
19 11.41 ICAM1 IL10 TNF
20 11.41 ICAM1 IL10 MMP9 TNF VCAM1
21 11.39 ICAM1 MMP9 TNF
22 11.31 ICAM1 IL10 TNF VCAM1
23 11.15 IFNB1 IL10 TNF
24 11.04 ICAM1 MMP9
25 11.02 IFNB1 TNF
26 11 ICAM1 IL10 TNF VCAM1
27 10.98 TNF VCAM1
28 10.89 CSF1R IFNB1 IL10 IL7R TNF
29 10.84 ICAM1 TNF VCAM1
30 10.46 MBP PLP1

GO Terms for Primary Progressive Multiple Sclerosis

Cellular components related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.26 ICAM1 IL7R TNF VCAM1
2 extracellular space GO:0005615 9.23 ICAM1 IFNB1 IL10 MMP9 OMG S100B

Biological processes related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.88 CSF1R IL10 PLP1 TNF
2 positive regulation of protein phosphorylation GO:0001934 9.77 CSF1R MMP9 TNF
3 regulation of cell shape GO:0008360 9.77 CSF1R ICAM1 S100B
4 cellular response to lipopolysaccharide GO:0071222 9.74 ICAM1 IL10 TNF
5 central nervous system development GO:0007417 9.73 MBP MOG S100B
6 B cell differentiation GO:0030183 9.63 IFNB1 IL10 VCAM1
7 extracellular matrix organization GO:0030198 9.62 ICAM1 MMP9 TNF VCAM1
8 osteoclast differentiation GO:0030316 9.61 CSF1R TNF
9 negative regulation of interleukin-6 production GO:0032715 9.61 IL10 TNF
10 response to glucocorticoid GO:0051384 9.61 IL10 S100B TNF
11 macrophage differentiation GO:0030225 9.58 CSF1R MMP9
12 leukocyte tethering or rolling GO:0050901 9.55 TNF VCAM1
13 negative regulation of growth of symbiont in host GO:0044130 9.54 IL10 TNF
14 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.52 IL10 TNF
15 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.51 IL10 MBP
16 axon ensheathment GO:0008366 9.49 MBP PLP1
17 endothelial cell apoptotic process GO:0072577 9.48 IL10 TNF
18 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.4 ICAM1 TNF
19 negative regulation of cytokine secretion involved in immune response GO:0002740 9.37 IL10 TNF
20 membrane to membrane docking GO:0022614 9.26 ICAM1 VCAM1
21 receptor biosynthetic process GO:0032800 9.16 IL10 TNF
22 B cell proliferation GO:0042100 9.13 IFNB1 IL10 IL7R
23 positive regulation of vascular smooth muscle cell proliferation GO:1904707 8.8 IL10 MMP9 TNF

Molecular functions related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of myelin sheath GO:0019911 8.62 MBP PLP1

Sources for Primary Progressive Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....